Effects of long-term testosterone treatment on weight loss and waist size in obese men - is TRT the next obesity treatment?
What is known
What this study adds
Figure from Saad et al. 2015 
* Note: When interpreting the elevations in testosterone levels (total and free), one has to bear in mind that these reported levels are trough levels, i.e. the lowest level measured immediately before the next injection. Pharmacokinetic data show that after one injection of testosterone undecanoate it takes 9 days to reach Cmax (concentration maximum, i.e. the peak level) at 923 ng/dL (32 nmol/L), and 70.2 days for half of the injected testosterone dose to be eliminated from the body (i.e. t½ = elimination half-life, is 70.2 days). Mean levels in the lower normal range – but significantly higher compared with baseline values – can be maintained until approximately 12 weeks after one injection. While these pharmacokinetic data were derived in non-obese men - and will likely differ in obese men – it does give a rough guideline when interpreting testosterone levels during testosterone treatment.
The figures below illustrate graphically the reductions in waist circumference, weight, BMI and percent weight loss.
All obesity groups also experienced significant improvements in metabolic parameters; glycemic control (fasting glucose and HbA1c), lipids (total cholesterol, LDL, HDL, triglycerides and total cholesterol:HDL ratio), liver transaminases, inflammation and blood pressure (both systolic and diastolic) all improved. This was accompanied by a marked and significantly increased quality of life, regardless of obesity class.
Comparison to traditional obesity treatments
1. Saad, F., The emancipation of testosterone from niche hormone to multi-system player. Asian J Androl, 2015. 17(1): p. 58-60.
2. Kelly, D.M. and T.H. Jones, Testosterone: a metabolic hormone in health and disease. J Endocrinol, 2013. 217(3): p. R25-45.
3. Yanovski, S.Z. and J.A. Yanovski, Long-term drug treatment for obesity: a systematic and clinical review. JAMA, 2014. 311(1): p. 74-86.
4. Dobbs, R., et al., Overcoming obesity: An initial economic analysis http://www.mckinsey.com/insights/economic_studies/how_the_world_could_better_fight_obesity Accessed December 1, 2014.
5. Jeffery, R.W., et al., Long-term maintenance of weight loss: current status. Health Psychol, 2000. 19(1 Suppl): p. 5-16.
6. Douketis, J.D., et al., Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond), 2005. 29(10): p. 1153-67.
7. Pekkarinen, T., J. Kaukua, and P. Mustajoki, Long-term weight maintenance after a 17-week weight loss intervention with or without a one-year maintenance program: a randomized controlled trial. J Obes, 2015. 2015: p. 651460.
8. Johansson, K., M. Neovius, and E. Hemmingsson, Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr, 2014. 99(1): p. 14-23.
9. Pownall, H.J., et al., Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the look AHEAD study. Obesity (Silver Spring), 2015. 23(3): p. 565-72.
10. Middleton, K.M., S.M. Patidar, and M.G. Perri, The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev, 2012. 13(6): p. 509-17.
11. Rueda-Clausen, C.F., R.S. Padwal, and A.M. Sharma, New pharmacological approaches for obesity management. Nat Rev Endocrinol, 2013. 9(8): p. 467-78.
12. Patham, B., D. Mukherjee, and Z.T. San Juan, Contemporary review of drugs used to treat obesity. Cardiovasc Hematol Agents Med Chem, 2013. 11(4): p. 272-80.
13. Saad, F., et al., Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity Classes I-III: Observational data from two registry studies. Int J Obes (Lond), 2015. Jul 29 [Epub ahead of print].
14. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, O.E.P., Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring), 2014. 22 Suppl 2: p. S41-410.
15. Finkelstein, E.A., et al., The lifetime medical cost burden of overweight and obesity: implications for obesity prevention. Obesity (Silver Spring), 2008. 16(8): p. 1843-8.
16. Haring, R., et al., Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male, 2010. 13(4): p. 247-57.
17. Grossmann, M., Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab, 2011. 96(8): p. 2341-53.
18. Pitteloud, N., et al., Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab, 2005. 90(5): p. 2636-41.
19. Mah, P.M. and G.A. Wittert, Obesity and testicular function. Mol Cell Endocrinol, 2010. 316(2): p. 180-6.
20. Cohen, P.G., The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med Hypotheses, 1999. 52(1): p. 49-51.
21. Yeap, B.B., et al., Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur J Endocrinol, 2009. 161(4): p. 591-8.
22. Tajar, A., et al., Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab, 2012. 97(5): p. 1508-16.
23. Pellitero, S., et al., Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg, 2012. 22(12): p. 1835-42.
24. Travison, T.G., et al., The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab, 2007. 92(2): p. 549-55.
25. Camacho, E.M., et al., Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol, 2013. 168(3): p. 445-55.
26. Francomano, D., et al., Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest, 2014. 37: p. 401-411.
27. Francomano, D., A. Lenzi, and A. Aversa, Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol, 2014. 2014: p. 527470.
28. Behre, H.M., et al., A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male, 2012. 15(4): p. 198-207.
29. Kapoor, D., et al., Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol, 2006. 154(6): p. 899-906.
30. Bhattacharya, R.K., et al., Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord, 2011. 11: p. 18.
31. Haider, A., et al., Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract, 2014. 8(4): p. e339-49.
32. Haider, A., et al., Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol, 2014. 2014: p. 683515.
33. Saad, F., et al., Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring), 2013. 21(10): p. 1975-81.
34. Yassin, A. and G. Doros, Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes, 2013. 3(3-4): p. 73-83.
35. Frederiksen, L., et al., Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr), 2012. 34(1): p. 145-56.
36. Birzniece, V., et al., Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): comparison of oral and transdermal testosterone administration in hypopituitary men. Clin Endocrinol (Oxf), 2009. 71(5): p. 715-21.
37. Host, C., et al., Independent effects of testosterone on lipid oxidation and VLDL-TG production: a randomized, double-blind, placebo-controlled, crossover study. Diabetes, 2013. 62(5): p. 1409-16.
38. Saad, F., et al., Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev, 2012. 8(2): p. 131-43.
39. Allan, C.A. and R.I. McLachlan, Androgens and obesity. Curr Opin Endocrinol Diabetes Obes, 2010. 17(3): p. 224-32.
40. von Eckardstein, S. and E. Nieschlag, Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl, 2002. 23(3): p. 419-25.
41. Wadden, T.A., et al., Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation, 2012. 125(9): p. 1157-70.
42. Look, A.R.G. and R.R. Wing, Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med, 2010. 170(17): p. 1566-75.
43. Neto, W.K., et al., Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age (Dordr), 2015. 37(1): p. 9742.